<PRE>
[Federal Register: August 9, 2002 (Volume 67, Number 154)]
[Notices]               
[Page 51862]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09au02-93]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

 
Nonclinical Studies Subcommittee of the Advisory Committee for 
Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Nonclinical Studies Subcommittee of the Advisory 
Committee for Pharmaceutical Science.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 9, 2002, from 
1 p.m. to 4:30 p.m. and September 10, 2002, from 8 a.m. to 12 noon.
    Location: Center for Drug Evaluation and Research, Advisory 
Committee conference room 1066, 5630 Fishers Lane, Rockville, MD.
    Contact Person: Kathleen Reedy, Center for Drug Evaluation and 
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for 
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 
301-827-7001, e-mail: <A HREF="mailto:reedyk@cder.fda.gov">reedyk@cder.fda.gov</A>, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 12539. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: On September 9, 2002, the Chair of the expert working group 
on cardiotoxicity will report on the progress and activities of the 
group and the subcommittee will be allotted time to discuss the report. 
The subcommittee will then discuss a plan to transfer oversight of the 
subcommittee from the Advisory Committee for Pharmaceutical Science to 
the Science Advisory Board of the National Center for Toxicological 
Research. On September 10, 2002, the Chair of the expert working group 
on vascular damage will report on the progress and activities of the 
group and the subcommittee members will be allotted time to discuss the 
report.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the subcommittee. 
Written submissions may be made to the contact person by August 23, 
2002. Oral presentations from the public will be scheduled between 
approximately 10 a.m. and 11 a.m. on September 10, 2002. Time allotted 
for each presentation may be limited. Those desiring to make formal 
oral presentations should notify the contact person before August 23, 
2002, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Carolyn Jones, 301-
827-7001, at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 2, 2002.
Linda Arey Skladany,
Senior Associate Commissioner for External Relations.
[FR Doc. 02-20162 Filed 8-8-02; 8:45 am]
BILLING CODE 4160-01-S

</PRE>